Idra 21 Powder

The core use of Idra-21 Powder is as a positive allosteric modulator of AMPA receptors, which enhances glutamate (Glu) - mediated excitatory synaptic transmission by inhibiting the rapid desensitization process of AMPA receptors, prolonging receptor activation time. This mechanism has significant value in neuroscience research, exploration of cognitive impairment treatment, and neuroprotection.

AMPA receptor is a type of ionotropic glutamate receptor (iGluR) that mediates approximately 70% of rapid excitatory synaptic transmission in the brain. Under continuous glutamate stimulation, AMPA receptors are prone to desensitization, leading to channel closure and signal interruption.

Idra-21 inhibits desensitization by binding to the allosteric site of AMPA receptors, allowing the receptors to remain open for longer periods of time in the presence of glutamate, thereby enhancing the decay time of postsynaptic currents. For example, in vitro hippocampal neuron experiments, Idra-21 (1-300 μ M) significantly prolonged the duration of excitatory postsynaptic current (EPSC) and improved neural transmission efficiency.

Compared to early AMPA modulators such as cyclothiazide, Idra-21 has stronger blood-brain barrier penetration ability, higher oral bioavailability, and lower neurotoxicity. Animal experiments have shown that Idra-21 causes almost no neuronal death at effective doses (0.15-10 mg/kg), while high-dose cyclosporine may induce hippocampal neuronal apoptosis.

The research of Idra-21 in the field of cognitive impairment is one of its core applications, especially in models of age-related cognitive decline, drug-induced cognitive impairment, etc. It has shown significant effects. Young rhesus monkeys:

Oral administration of Idra-21 (0.15-10 mg/kg, once every three days, for 3 weeks) can significantly improve the accuracy of DMTS tasks, especially in the long delay (most difficult) experiment, where the task accuracy increased by 34% compared to the control group.

After a single administration, the effect lasted for 48 hours, and after three weeks of intermittent administration, the cognitive improvement effect remained stable. Elderly rhesus monkeys: Although Idra-21 (within the same dosage range) can improve task accuracy, its effect is weaker than that of young individuals, and elderly monkeys are more sensitive to drug dosage, resulting in shorter task latency.

This indicates that Idra-21 has the potential to intervene in age-related cognitive decline, but individualized dose adjustments are needed. In an adult rat model of global cerebral ischemia, Idra-21 (6-24 mg/kg, gavage, single dose) can increase ischemia induced G41 neuron damage, suggesting its potential neuroprotective role in ischemic injury.

However, high doses (300 μ M, 30 minutes) may induce hippocampal neuron death in vitro experiments, and the dosage range needs to be strictly controlled. Compared to classical cognitive enhancers such as amphetamines, Idra-21 has a longer duration of action. The improvement effect of amphetamines in the DMTS task of rhesus monkeys only lasts for 2-4 hours, while the effect of Idra-21 continues for 48 hours after a single dose, reducing the need for frequent administration and improving treatment compliance.

Idra 21 Powder, as a highly selective AMPA receptor PAM, is widely used in basic neuroscience research to help reveal the mechanism of glutamatergic system in synaptic plasticity, learning and memory. AMPA receptors are key mediators of long-term potentiation (LTP) and long-term inhibition (LTD).

Idra-21 can enhance LTP induction efficiency by prolonging AMPA receptor activation time, providing a tool for studying synaptic plasticity. For example, in hippocampal slice experiments, Idra-21 significantly increased the amplitude of LTP induced by high-frequency stimulation, revealing the core role of AMPA receptor desensitization in synaptic plasticity regulation.

The binding of Idra-21 to AMPA receptors does not directly activate the receptors, but enhances the effect of glutamate through allosteric regulation, avoiding excitotoxicity caused by overactivation. This characteristic makes it an ideal tool for studying the signaling pathways of the glutamatergic system, which can distinguish the physiological differences between direct activation and allosteric regulation.

From rodents (rats, mice) to non-human primates (rhesus monkeys), Idra-21 has shown consistent cognitive improvement effects in various animal models, verifying the conservation of its mechanism of action. This provides cross species evidence support for the translation from basic research to clinical practice.

Based on its cognitive enhancement and neuroprotective effects, Idra-21 has potential application value in the treatment of the following diseases, but further clinical validation is needed: decreased expression of AMPA receptors in the hippocampus and impaired synaptic plasticity in AD patients.

Idra-21 may improve cognitive symptoms in AD patients by enhancing AMPA receptor function. Animal experiments have shown that Idra-21 can reverse spatial memory deficits in AD model mice, but the distribution of target tissues after penetrating the blood-brain barrier needs to be addressed.

Schizophrenia patients have deficits in working memory and cognitive flexibility, which are associated with insufficient glutamate transmission in the prefrontal cortex. Idra-21 may improve cognitive symptoms by enhancing AMPA receptor function in the prefrontal cortex. Preclinical studies have shown that Idra-21 can enhance working memory performance in schizophrenia model rats, but its interaction with antipsychotic drugs needs to be evaluated.

The neuroprotective effect of Idra-21 in a global cerebral ischemia model suggests its potential use in the treatment of acute stroke. The mechanism may be related to the inhibition of excitotoxicity caused by excessive activation of AMPA receptors, but it is necessary to balance its neuroprotection with potential neurotoxicity risks.